Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4561 to 4575 of 7691 results

  1. Further data collection and research are recommended to assess the effectiveness of treatment options for bile acid diarrhoea. Consideration should be given to how well the treatments are tolerated and how they affect the severity of symptoms in the longer term.

    Recommendation ID DG44/03 Question Further data collection and research are recommended to assess the effectiveness of treatment options

  2. Further data collection and research are recommended to understand how SeHCAT (tauroselcholic [75 selenium] acid) test results affect clinical decision making.

    Recommendation ID DG44/01 Question Further data collection and research are recommended to understand how SeHCAT (tauroselcholic [75 selenium]

  3. Further data collection or research is recommended on the impact of implementing MRI fusion biopsy systems on the rate at which biopsies can be done, capacity resources and waiting times for this procedure.

    Recommendation ID DG53/2 Question Further data collection or research is recommended on the impact of implementing MRI fusion biopsy systems

  4. Further good quality evidence is needed to address uncertainties about myCOPD's clinical benefits and its effect on healthcare resource use. myCOPD has potential for clinical benefits, but more evidence is needed to reduce uncertainties. The committee considered that comparative evidence is needed to show the clinical benefits of using myCOPD in 2 populations: people using it to self-manage COPD people referred to pulmonary rehabilitation For self-management, a randomised controlled trial is preferred to show the clinical benefits of myCOPD. This could be powered based on the encouraging results in the RESCUE study. However, a high-quality comparative observational study designed to minimise bias in the results may provide acceptable evidence. Outcomes such as rates of exacerbations, hospital readmissions and unscheduled care appointments should be considered alongside patient-reported outcomes such as health-related quality of life. For pulmonary rehabilitation, further evidence is needed to show the clinical benefits of myCOPD. This could be a randomised controlled trial which is powered based on the encouraging results in the TROOPER study or a well-designed comparative observational study. Key outcomes will be the CAT score and 6-minute walk test, ideally supported by additional longer-term outcomes such as rates of exacerbations and hospital admissions. Real-world data could be used to inform the uptake rates in the economic modelling. It should also include qualitative data on patient experience using myCOPD such as patient preferences and adherence.

    Recommendation ID MTG68/01 Question Further good quality evidence is needed to address uncertainties about myCOPD's clinical benefits and

  5. Further primary research is recommended on the clinical effectiveness of using ELISA tests for therapeutic monitoring of TNF‑alpha inhibitors in people with rheumatoid arthritis.

    Recommendation ID DG36/1 Question Further primary research is recommended on the clinical effectiveness of using ELISA tests for therapeutic

  6. Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.

    Recommendation ID TA214/1 Question Further research designed to investigate differences in health-related quality of life and the clinical

  7. Active surveillance compared with surgery: For people with stage 1 differentiated thyroid cancer, what is the clinical and cost effectiveness of active surveillance compared with surgery?

    Recommendation ID NG230/03 Question Active surveillance compared with surgery: For people with stage 1 differentiated thyroid cancer, what

  8. FRAX and QFracture in adults receiving bone protective therapy:- What is the utility of FRAX and QFracture in adults receiving bone protective therapy?

    Recommendation ID CG146/2 Question FRAX and QFracture in adults receiving bone protective therapy:- What is the utility of FRAX and QFracture